Source disclosure: February 09, 2026
Kringle Pharma,Inc. [4884.T]
TOKYO, Feb 09 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) reported a net loss of ¥72 million for the quarter ending December 2025, compared to ¥18 million in the same period last year.
Operating expenses increased due to preparations for regulatory approval of its spinal injury treatment and clinical trial costs for vocal scar therapy. In the spinal injury acute phase, the company completed enrollment in its Phase III trials, achieving target case numbers. However, the effectiveness varied between patient groups based on age and injury severity. Despite challenges, Kringle Pharma plans additional clinical trials to gather more efficacy data before submitting for approval.
For vocal scar treatment, the company concluded its Phase III trial, meeting all primary endpoints. The study involved 65 patients across eight facilities and demonstrated significant improvements in voice handicap scores and vocal fold vibratory amplitudes. Kringle Pharma expects to advance towards commercialization based on these positive results. Additionally, the company secured funding through partnerships, including a $93.5 million Series B round led by Claris Biotherapeutics, which also expanded collaboration agreements to enhance manufacturing efficiency and accelerate global development of therapies targeting fibrotic diseases.
AI-translated content. 🟢 Confidence: High See terms • Original filing